Centessa's $7.8B Lilly Buyout Closes; Biotech M&A Boom Continues
UK court approves Lilly's $7.8B Centessa acquisition The UK High Court approved Eli Lilly's $7.8 billion buyout of Centessa. Shareholders get $38 per share in cash plus a contingent value right worth up to $9 more if milestones are met. This locked in the deal price and removed uncertainty, pushing CNTA toward the buyout value.
This is the key regulatory approval that made the buyout final and set the exact payout for shareholders.
Lilly completes Centessa acquisition; CNTA delisted Eli Lilly closed its acquisition of Centessa on June 24, 2026. CNTA shares stopped trading on Nasdaq, and shareholders received the cash and CVR payout. This is the final step that turned the buyout into real money for investors.
This is the event that ended CNTA's life as a public stock and delivered the buyout proceeds to shareholders.
Biopharma M&A hits six-year high, validating Centessa's sale PwC reported Q1 2026 pharma deal value topped $65 billion, the strongest since 2020, driven by a huge patent cliff. Lilly's $7.8 billion Centessa purchase was a highlight. This confirms Centessa was bought in a hot market, supporting the deal price and CVR potential.
It shows the broader M&A boom that made Centessa's buyout possible and validates the valuation.
Biotech named hottest market group after Centessa deal Jim Cramer called biotech the hottest group, citing a 51% biotech ETF gain and a deal surge under new FDA leadership. He noted Lilly's acquisitions, including Centessa. This keeps investor attention on biotech M&A, which can lift CVR expectations and similar stocks.
It reflects ongoing market enthusiasm for biotech deals, which supports the value of Centessa's CVR and the sector.